MD20150018A2 - Compoziţie cu acţiune transdermală ce conţine inhibitori ai ciclooxigenazei-2 - Google Patents

Compoziţie cu acţiune transdermală ce conţine inhibitori ai ciclooxigenazei-2

Info

Publication number
MD20150018A2
MD20150018A2 MDA20150018A MD20150018A MD20150018A2 MD 20150018 A2 MD20150018 A2 MD 20150018A2 MD A20150018 A MDA20150018 A MD A20150018A MD 20150018 A MD20150018 A MD 20150018A MD 20150018 A2 MD20150018 A2 MD 20150018A2
Authority
MD
Moldova
Prior art keywords
inhibitors
formulation containing
transdermal formulation
cyclooxygenase
active compound
Prior art date
Application number
MDA20150018A
Other languages
English (en)
Russian (ru)
Inventor
Эндре Микулашик
Тамаш СПАЙТС
СИНКА Агота САКАЙНЕ
Original Assignee
Egis Gyogyszergyar Zrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20150018(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Egis Gyogyszergyar Zrt. filed Critical Egis Gyogyszergyar Zrt.
Publication of MD20150018A2 publication Critical patent/MD20150018A2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se revendică compoziţii sub formă de gel, acceptabile pentru administrarea topică, care conţin un compus activ cu acţiune transdermală cu solubilitate scăzută, de exemplu a compuşilor inhibitori de COX-2, procedee de preparare şi de utilizare a acestora pentru tratamentul patologiilor care urmează a fi tratate cu acest compus activ.
MDA20150018A 2012-07-31 2013-07-31 Compoziţie cu acţiune transdermală ce conţine inhibitori ai ciclooxigenazei-2 MD20150018A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/562,686 US10045935B2 (en) 2012-07-31 2012-07-31 Transdermal formulation containing COX inhibitors
PCT/HU2013/000080 WO2014020366A1 (en) 2012-07-31 2013-07-31 Transdermal formulation containing cox inhibitors

Publications (1)

Publication Number Publication Date
MD20150018A2 true MD20150018A2 (ro) 2015-07-31

Family

ID=49231593

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150018A MD20150018A2 (ro) 2012-07-31 2013-07-31 Compoziţie cu acţiune transdermală ce conţine inhibitori ai ciclooxigenazei-2

Country Status (40)

Country Link
US (2) US10045935B2 (ro)
EP (1) EP2879664B1 (ro)
JP (3) JP6374383B2 (ro)
KR (1) KR20150032892A (ro)
CN (1) CN104768530B (ro)
AU (2) AU2013298294A1 (ro)
BR (1) BR112015002041B1 (ro)
CA (1) CA2880442C (ro)
CL (1) CL2015000240A1 (ro)
CO (1) CO7240432A2 (ro)
CR (1) CR20150044A (ro)
CU (1) CU24246B1 (ro)
CY (1) CY1123805T1 (ro)
DK (1) DK2879664T3 (ro)
EA (1) EA033950B1 (ro)
EC (1) ECSP15003613A (ro)
ES (1) ES2841992T3 (ro)
GE (1) GEP20176630B (ro)
HK (1) HK1211490A1 (ro)
HR (1) HRP20210008T1 (ro)
HU (1) HUE053418T2 (ro)
IL (1) IL236988B (ro)
IN (1) IN2015DN01329A (ro)
LT (1) LT2879664T (ro)
MA (1) MA37880B1 (ro)
MD (1) MD20150018A2 (ro)
MX (1) MX361697B (ro)
NI (1) NI201500007A (ro)
NZ (1) NZ704567A (ro)
PE (1) PE20150755A1 (ro)
PH (1) PH12015500200A1 (ro)
PL (1) PL2879664T3 (ro)
PT (1) PT2879664T (ro)
RS (1) RS61326B1 (ro)
SG (1) SG11201500734SA (ro)
SI (1) SI2879664T1 (ro)
TN (1) TN2015000037A1 (ro)
UA (1) UA116636C2 (ro)
WO (1) WO2014020366A1 (ro)
ZA (1) ZA201500744B (ro)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045935B2 (en) * 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CN108904812A (zh) * 2018-08-27 2018-11-30 邛崃市医疗中心医院 以卡波姆协同透皮剂的高透皮性防治肩周炎的外用药物
CN114601789B (zh) * 2022-03-29 2024-03-26 辽宁方诺生物科技有限公司 一种塞来昔布凝胶剂及其制备方法和应用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998973A (en) 1975-04-07 1976-12-21 R. T. Vanderbilt Company, Inc. Thickening composition
FR2339392A1 (fr) 1976-02-02 1977-08-26 Oreal Compositions contenant des derives du silicium
GB2050160A (en) 1979-04-10 1981-01-07 Nottage H C Cosmetic protective cream
FR2471778A1 (fr) 1979-12-21 1981-06-26 Oreal Procede de traitement des cheveux en vue d'ameliorer leur aspect a l'aide d'une composition contenant un hydrolysat de lactalbumine
WO1984001710A1 (en) 1982-11-04 1984-05-10 Redken Laboratories Inc Cosmetic preparation
GB8320366D0 (en) 1983-07-28 1983-09-01 Gillette Co Hair relaxing compositions
GB8421112D0 (en) 1984-08-20 1984-09-26 Unilever Plc Pyroglutamic acid esters
GB8600568D0 (en) 1986-01-10 1986-02-19 Gillette Co Hair relaxing compositions
US4831023A (en) 1986-06-27 1989-05-16 Thames Pharmacal Co., Inc. Water washable vehicles for topical use
US4837019A (en) 1986-08-11 1989-06-06 Charles Of The Ritz Group Ltd. Skin treatment composition and method for treating burned skin
DE3805744C2 (de) 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US4720353A (en) 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
DE3714140A1 (de) 1987-04-28 1988-11-10 Lohmann Therapie Syst Lts Wirkstoffhaltiges pflaster zur kontrollierten verabreichung von wirkstoffen an die haut, seine verwendung sowie verfahren zur gesteuerten verabreichung von wirkstoffen an die haut
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JPH02145512A (ja) 1988-11-26 1990-06-05 Shin Etsu Chem Co Ltd 被膜形成型外用剤
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
DE4131678A1 (de) 1991-04-13 1992-10-15 Beiersdorf Ag Stabile multiple emulsionen
JPH06509099A (ja) 1991-07-03 1994-10-13 サノ・コーポレーシヨン ジクロフエナツクの経皮デリバリーに対する組成物及び方法
US5300286A (en) 1992-07-14 1994-04-05 Dow Corning Corporation Silicone emulsion for personal care application
US5210103A (en) 1992-09-02 1993-05-11 Basf Corporation Volatile silicone oil-blown integral skin foam
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9315755D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized formulation
FR2709131B1 (fr) 1993-08-18 1995-11-10 Cilag Laboratoire Dispositif de distribution d'une substance thérapeutique ou cosmétique dont le véhicule inerte est un polydiorganosiloxane volatil, et composition destinée à être utilisée dans le dispositif.
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5620692A (en) 1993-12-23 1997-04-15 Nurture, Inc. Oat oil compositions with useful cosmetic and dermatological properties
GB9404248D0 (en) 1994-03-05 1994-04-20 Boots Co Plc Pharmaceutical formulations
US5451405A (en) 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
IL116539A (en) 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
FR2738565B1 (fr) 1995-09-13 1997-11-28 Dior Christian Parfums Produits extraits d'une plante du genre commiphora, en particulier de la plante commiphora mukul, et extraits en contenant et leurs applications notamment en cosmetique
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AU2456097A (en) 1996-05-21 1997-12-09 Dermasciences, Inc. Topical barrier composition containing silicone and bentonite
GB9611167D0 (en) 1996-05-29 1996-07-31 Glaxo Group Ltd Medicaments
JP2001501913A (ja) 1996-06-28 2001-02-13 ユニリーバー・ナームローゼ・ベンノートシヤープ 液体制汗／防臭組成物
FR2751874B1 (fr) 1996-08-02 1998-08-28 Sederma Sa Nouvelles compositions cosmetiques pour embellir et eclaircir la peau
GB9618974D0 (en) 1996-09-11 1996-10-23 Glaxo Group Ltd Medicaments
US5756109A (en) 1996-09-27 1998-05-26 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing geranyl geraniol and retinol or retinyl esters
US5747051A (en) 1996-09-27 1998-05-05 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6019997A (en) 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19700913C2 (de) 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
FR2763842B1 (fr) 1997-05-27 2000-09-15 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques contenant des derives de threonine ou de serine
FR2768335B1 (fr) 1997-09-12 2000-03-03 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant une association d'extrait d'algue et d'exopolysaccharide
IL122084A (en) 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
DE19750030A1 (de) 1997-11-12 1999-05-20 Merck Patent Gmbh Lichtstabile kosmetische Formulierung enthaltend Butylmethoxydibenzoylmethan
DE19750029A1 (de) 1997-11-12 1999-05-20 Merck Patent Gmbh Stabile kosmetische Formulierung enthaltend Butylmethoxydibenzoylmethan
US6187300B1 (en) 1997-12-17 2001-02-13 The Procter & Gamble Company Antiperspirant cream compositions having improved wash-off and antiperspirant efficacy
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US20060015058A1 (en) 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
CN1311665A (zh) 1998-08-03 2001-09-05 新生制药公司 一种新的止痛、抗炎和创伤治疗剂
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
GB9828379D0 (en) 1998-12-22 1999-02-17 Unilever Plc Skin care composition
US6007829A (en) 1998-12-17 1999-12-28 Cheesebrough-Pond's Usa Co. Cosmetic skin care compositions containing succinate compounds
FR2791887B1 (fr) 1999-04-06 2004-04-23 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques renfermant des extraits vegetaux de pinus lambertania contre la secheresse cutanee de toute origine
HU230045B1 (hu) 1999-04-23 2015-06-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Bőrgyógyászati alkalmazásra szolgáló nem vizes gyógyszerkészítmény
KR100319473B1 (ko) 1999-08-24 2002-01-05 김강권 실크아미노산 수용액을 주재로한 아이스크림류의 제조방법
US10179159B2 (en) 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
FR2802097B1 (fr) 1999-12-14 2002-12-13 Invest S Therapeutiques Essais Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
US20050074487A1 (en) 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
DE10004790B4 (de) 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
US6361806B1 (en) 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue
ES2290120T3 (es) 2000-03-17 2008-02-16 Avocet Polymer Technologies, Inc. Procedimientos para mejorar la dimension y el aspecto de una herida.
US6800297B2 (en) 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
US6589557B2 (en) 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
DE10032132A1 (de) 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
IN191090B (ro) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
DE10042411A1 (de) 2000-08-30 2002-03-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Exemestan
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
GB0027769D0 (en) 2000-11-14 2000-12-27 Unilever Plc Cosmetic method of treating skin
GB0028355D0 (en) 2000-11-21 2001-01-03 Unilever Plc Cosmetic method of treating skin
GB0028706D0 (en) 2000-11-24 2001-01-10 Unilever Plc Cosmetic composition
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CZ20033241A3 (cs) 2001-05-31 2004-08-18 Pharmaciaácorporation Kůži prostupující přípravek obsahující selektivně inhibující cyklooxygenázu@@ a jednosytný alkohol
GB0119583D0 (en) 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
WO2003035080A2 (en) * 2001-08-28 2003-05-01 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
US20030104019A1 (en) 2001-11-01 2003-06-05 Mcculloch Laura Composition for reducing enzymatic irritation to skin
DE10164531A1 (de) 2001-12-31 2003-07-17 Pharmatech Gmbh Zubereitung zur Oberflächenanästhesie der Haut
US6838078B2 (en) 2002-01-16 2005-01-04 3M Innovative Properties Company Film-forming compositions and methods
US20030180281A1 (en) 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
EP1490030B2 (en) 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
US20030199584A1 (en) 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US20030199537A1 (en) 2002-04-18 2003-10-23 Cannon John B. Polymorph of a pharmaceutical
JP2004075592A (ja) 2002-08-14 2004-03-11 Masahiko Abe 非イオン性ベシクルおよびその利用
CH696420A5 (de) 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
US20060241175A1 (en) 2002-09-27 2006-10-26 Joseph Schwarz Vehicle for topical delivery of anti-inflammatory compounds
US7138394B2 (en) 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
JP2006523628A (ja) 2003-04-18 2006-10-19 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 配合物
ITRM20030204A1 (it) 2003-04-29 2004-10-30 Provincia Italiana Della Congregazi One Dei Figli Formulazione dermatologica.
FR2854897B1 (fr) 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
WO2004112837A1 (ja) 2003-05-23 2004-12-29 Hisamitsu Pharmaceutical Co., Inc. 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン－１α生成抑制剤
US9248088B2 (en) 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
WO2005007129A2 (en) 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
AU2004261063A1 (en) 2003-08-04 2005-02-10 Foamix Ltd. Foam carrier containing amphiphilic copolymeric gelling agent
WO2005016292A1 (en) 2003-08-07 2005-02-24 The Procter & Gamble Company Oil emulsions
WO2005044227A1 (en) 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
WO2005046600A2 (en) 2003-11-07 2005-05-26 Nexmed Holdings, Inc. Transdermal tulobuterol delivery
FR2862871B1 (fr) 2003-12-01 2008-05-30 Camet Anne Dupouy Composition cosmetique anti-pollution
US7662855B2 (en) 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
US20050255133A1 (en) 2004-05-11 2005-11-17 Alpharx Inc. Topical composition for acne treatment
US20050255131A1 (en) 2004-05-11 2005-11-17 Mohan Vishnupad Clindamycin compositions and delivery system therefor
EP1784150A4 (en) 2004-09-01 2011-05-11 Nexmed Holdings Inc TRANSDERMAL DELIVERY SYSTEM FOR ANTIEMETIC COMPOSITION
US20070267035A1 (en) 2004-09-07 2007-11-22 Henkel Kommanditgesellschaft Auf Aktien Composition and Method for the Smoothing of Fibres Containing Keratin
US8653055B2 (en) 2004-09-15 2014-02-18 Teva Animal Health, Inc. Corticosteroid having low systemic absorption
TW200616589A (en) 2004-10-08 2006-06-01 Noven Pharma Transdermal delivery of drugs based on crystal size
WO2006091297A2 (en) 2005-02-23 2006-08-31 The Regents Of The University Of California Molecules to enhance percutaneous delivery and methods for discovery therefor
WO2006138035A1 (en) 2005-06-13 2006-12-28 Dow Corning Corporation Vehicle for the delivery of topical lipid soluble pharmaceutical agents
CA2618993A1 (en) 2005-08-13 2007-02-22 Collegium Pharmaceutical, Inc. Topical delivery with a carrier fluid
WO2007051596A1 (en) 2005-11-03 2007-05-10 Dsm Ip Assets B.V. Novel retinyl biotinates and use thereof
KR100658436B1 (ko) 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
EP1978997A1 (en) 2005-12-22 2008-10-15 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
HUP0900072A2 (hu) 2009-02-06 2010-09-28 Egis Gyogyszergyar Nyilvanosan Transzdermális gyógyszerkészítmények
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
WO2009010837A2 (en) 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
WO2009031318A1 (ja) 2007-09-05 2009-03-12 Kowa Co., Ltd. 鎮痛・抗炎症剤含有外用剤
WO2009063367A1 (en) 2007-11-15 2009-05-22 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief
US20100105750A1 (en) 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US20120004306A1 (en) 2009-03-11 2012-01-05 Kowa Co., Ltd. External preparation containing analgesic/anti-inflammatory agent
CN102341123A (zh) 2009-03-11 2012-02-01 兴和株式会社 含有镇痛-抗炎症剂的外用剂
EP2575813A1 (en) * 2010-05-28 2013-04-10 Nuvo Research Inc. Topical etoricoxib formulation
US10045935B2 (en) * 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors

Also Published As

Publication number Publication date
HUE053418T2 (hu) 2021-07-28
PH12015500200A1 (en) 2015-03-16
CU24246B1 (es) 2017-02-02
ES2841992T3 (es) 2021-07-12
AU2013298294A1 (en) 2015-02-26
JP2015523408A (ja) 2015-08-13
BR112015002041A2 (pt) 2017-07-04
ECSP15003613A (es) 2015-12-31
PT2879664T (pt) 2021-01-13
CO7240432A2 (es) 2015-04-17
ZA201500744B (en) 2016-10-26
CL2015000240A1 (es) 2015-09-11
US20140037738A1 (en) 2014-02-06
GEP20176630B (en) 2017-02-27
IL236988B (en) 2019-06-30
HK1211490A1 (en) 2016-05-27
BR112015002041B1 (pt) 2022-11-16
MA37880A1 (fr) 2016-02-29
NZ704567A (en) 2018-02-23
KR20150032892A (ko) 2015-03-30
NI201500007A (es) 2015-06-10
US20150231247A1 (en) 2015-08-20
CA2880442C (en) 2020-10-27
JP2018100299A (ja) 2018-06-28
CA2880442A1 (en) 2014-02-06
EP2879664B1 (en) 2020-10-07
JP7210833B2 (ja) 2023-01-24
UA116636C2 (uk) 2018-04-25
CU20150010A7 (es) 2015-08-27
RS61326B1 (sr) 2021-02-26
MX361697B (es) 2018-12-14
JP6374383B2 (ja) 2018-08-15
CR20150044A (es) 2015-07-01
IL236988A0 (en) 2015-03-31
IN2015DN01329A (ro) 2015-07-03
AU2018202875B2 (en) 2019-12-12
PL2879664T3 (pl) 2021-06-28
CN104768530A (zh) 2015-07-08
TN2015000037A1 (en) 2016-06-29
WO2014020366A1 (en) 2014-02-06
MA37880B1 (fr) 2016-09-30
JP7384885B2 (ja) 2023-11-21
PE20150755A1 (es) 2015-06-07
EP2879664A1 (en) 2015-06-10
CY1123805T1 (el) 2022-05-27
EA033950B1 (ru) 2019-12-12
SI2879664T1 (sl) 2021-02-26
JP2022022374A (ja) 2022-02-03
HRP20210008T1 (hr) 2021-03-05
US10045935B2 (en) 2018-08-14
AU2018202875A1 (en) 2018-05-17
DK2879664T3 (da) 2021-01-11
SG11201500734SA (en) 2015-02-27
CN104768530B (zh) 2018-08-21
MX2015001387A (es) 2015-09-16
LT2879664T (lt) 2021-01-25
EA201590269A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12017502141A1 (en) Compounds and their methods of use
PH12016502355A1 (en) Pharmaceutical composition
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
PH12016501462A1 (en) Neprilysin inhibitors
PH12016502352A1 (en) Pharmaceutical composition
CY1123805T1 (el) Διαδερμικο σκευασμα που περιεχει αναστολεις cox
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
TW201613578A (en) Pharmaceutical combinations
MX2016005437A (es) Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3 -carboxamida como inhibidores de glucosilceramida sintasa.
WO2014179154A3 (en) Novel compounds that are erk inhibitors
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
WO2015156674A3 (en) Method for treating cancer
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)